Arthralgia and Medication Adherence in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.
- Estimate the incidence, time to onset, prevalence, and clinical and demographic
predictors of arthralgia in post-menopausal women with early-stage breast cancer
receiving aromatase inhibitors (AI).
- Chart the trajectory of arthralgia symptom severity over the course of AI treatment in
- Measure the impact of arthralgia on sleep quality, depression, and physical function in
- Develop a roster of current physician-advised or prescribed treatments, including
self-management techniques being used for AI-induced arthralgia, for intervention
OUTLINE: Patients complete questionnaires about joint pain and stiffness, sleep, depression,
physical function, medications and treatment, exercise and social support, demographics,
comorbidities, body mass index (BMI), and performance status at baseline and then
periodically for approximately 1 year after beginning aromatase inhibitor (AI) therapy.
Patient medical records are reviewed for comorbidities, BMI, use of prior hormone
replacement therapy, vitamin D levels and deficiency, performance status, histological
stage, prior treatment, and medications at baseline and then periodically for approximately
1 year after beginning AI therapy.
Observational Model: Cohort, Time Perspective: Prospective
Arthralgia incidence, defined as proportion of the baseline population (those who have taken ≥ 9 doses of aromatase inhibitor [AI]) in which new or worsening joint pain or stiffness is observed at 1, 3, and 12 months after beginning AI therapy
Liana Castel, PhD, MSPH
Vanderbilt-Ingram Cancer Center
United States: Institutional Review Board
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|